2
Total investments
2
Early stage
0
Mid stage
0
Late stage
11y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
CEO and Board member
Mar 2019
Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma’s therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease.
CEO and Board member
Nov 2015
INOFEA empowers enzymes.
Enzyme stabilization and protection is INOFEA`s core business. We have developed an innovative and patented platform technology to provide enzymes with a protective shield. We unlock the full potential value of enzymes, providing a seamless level of enhanced properties, unlike any other existing technology. This makes your enzymes 10 times more stable and they can be re-used easily. Our highly resistant enzymes support Biocatalysis including bioconjugation, diagnostics (bioanalysis) or can be formulated as active ingredients. Our technology addresses a wide range of biotech applications for the industry and demonstrated substantial benefits to customers in pharma, food processing, specialty chemicals and consumer care.
Experience · 4 entries
All (4)
Investments (2)
Founder (2)
Board (2)
2019
CEO and Board member
Mar 2019
Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma’s therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease.
2015
CEO and Board member
Nov 2015
INOFEA empowers enzymes.
Enzyme stabilization and protection is INOFEA`s core business. We have developed an innovative and patented platform technology to provide enzymes with a protective shield. We unlock the full potential value of enzymes, providing a seamless level of enhanced properties, unlike any other existing technology. This makes your enzymes 10 times more stable and they can be re-used easily. Our highly resistant enzymes support Biocatalysis including bioconjugation, diagnostics (bioanalysis) or can be formulated as active ingredients. Our technology addresses a wide range of biotech applications for the industry and demonstrated substantial benefits to customers in pharma, food processing, specialty chemicals and consumer care.
2010
E
ENVOLURE SAS (now AMS ENVOLURE part of AMS France)
Co-founder and President
Jan 2010
A
Co-founder and President
Jan 2010
AMS ENVOLURE is a research company based out of 10 AVENUE CHARLES DE GAULLE, FREPILLON, France.
